Abbott Laboratories (NYSE:ABT – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Abbott Laboratories to similar businesses based on the strength of its valuation, profitability, institutional ownership, earnings, risk, analyst recommendations and dividends.
Earnings & Valuation
This table compares Abbott Laboratories and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Abbott Laboratories | $44.33 billion | $6.52 billion | 38.99 |
| Abbott Laboratories Competitors | $1.89 billion | $136.81 million | 5.74 |
Abbott Laboratories has higher revenue and earnings than its competitors. Abbott Laboratories is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Dividends
Profitability
This table compares Abbott Laboratories and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Abbott Laboratories | 9.75% | 18.04% | 9.09% |
| Abbott Laboratories Competitors | -190.60% | -186.87% | -21.75% |
Insider and Institutional Ownership
75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Abbott Laboratories has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Abbott Laboratories’ competitors have a beta of 2.58, indicating that their average share price is 158% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and target prices for Abbott Laboratories and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abbott Laboratories | 0 | 5 | 21 | 2 | 2.89 |
| Abbott Laboratories Competitors | 4320 | 10605 | 18414 | 839 | 2.46 |
Abbott Laboratories presently has a consensus target price of $118.32, suggesting a potential upside of 13.24%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 26.40%. Given Abbott Laboratories’ competitors higher possible upside, analysts plainly believe Abbott Laboratories has less favorable growth aspects than its competitors.
Summary
Abbott Laboratories beats its competitors on 11 of the 15 factors compared.
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
